Editas Medicine and Beam Therapeutics, two firms working on CRISPR gene editor technology, are rumored to be close to a deal. Both firms shot up over 20% today in trading, despite both firms declining to comment on the issue.
Editas Medicine and Beam Therapeutics are rumored to be close to a deal.